The selective peroxisome proliferator-activated receptor alpha modulator (SPPARM) paradigm: conceptual framework and therapeutic potential: A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation
Erstveröffentlichung
2019
Wissenschaftlicher Artikel
Published in
Cardiovascular Diabetology ; 18 (2019). - Art.-Nr. 71. - ISSN 1475-2840